Focal cerebral ischemia: pathophysiologic mechanisms and rationale for future avenues of treatment.
Although approximately 500,000 patients suffer from a stroke each year in the United States, treatment of these patients to date has consisted primarily of prevention, supportive measures, and rehabilitation. The modification of experimental cerebral infarction by new pharmacologic agents, along with encouraging results from the restoration of blood flow to areas of focal ischemia in both laboratory and clinical trials, suggests that a more aggressive approach might be considered in selected patients with acute stroke.
D000925:Anticoagulants / Q000627:therapeutic use; D001463:Barbiturates / Q000627:therapeutic use; D001929:Brain Edema / Q000503:physiopathology; D002545:Brain Ischemia / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002548:Cerebral Revascularization; D002560:Cerebrovascular Circulation; D005466:Fluorocarbons / Q000627:therapeutic use; D006438:Hemodilution; D006801:Humans; D008353:Mannitol / Q000627:therapeutic use; D008833:Microcirculation; D009270:Naloxone / Q000627:therapeutic use
D000925:Anticoagulants; D001463:Barbiturates; D002121:Calcium Channel Blockers; D005466:Fluorocarbons; D009270:Naloxone; D008353:Mannitol